ACROBiosystems and SeromYx Systems Partner to Advance Anti-CD20 Monoclonal Antibody Research Through Comprehensive Functional Profiling

ACROBiosystemsSearch company, a biopharmaceutical industry cornerstone company, has announced a strategic research collaboration with SeromYx SystemsSearch company to advance the understanding of anti-CD20 monoclonal antibodiesSearch drug through comprehensive functional profiling. The partnership, announced on April 30, 2026, aims to unlock new insights into the therapeutic safety and efficacy drivers of these critical cancer and autoimmune disease treatments.

Novel Platform Integration Drives Discovery

The collaboration leverages ACROBiosystemsSearch company' recombinant human full-length CD20Search term virus-like particles (VLPs) combined with SeromYx's biophysical and cellular Fc-effector function platform. This integrated approach enables researchers to comprehensively analyze the function of approved anti-CD20 monoclonal antibodiesSearch drug, providing unprecedented insights into their mechanisms of action.

CD20Search term serves as a critical therapeutic target for treating B-cell malignanciesSearch disease and autoimmune diseasesSearch disease due to its selective expression on B-cells. This selectivity allows for effective B-cell depletion while preserving long-term immune memory, making it an attractive target for therapeutic intervention.

Comparative Analysis Reveals Distinct Mechanisms

The study conducted a detailed comparative analysis of three approved anti-CD20 monoclonal antibodiesSearch drug: RituximabSearch drug (RTX), OfatumumabSearch drug (OFA), and ObinutuzumabSearch drug (OBZ). The research revealed robust binding profiles and distinct Fc-effector functions across these therapeutic antibodies, providing valuable insights into their individual mechanisms of action.

Breakthrough Discovery of New Effector Functions

A significant outcome of the collaboration was the discovery of previously unknown Fc-effector functions, including antibody-dependent neutrophil and eosinophil phagocytosis activities. These findings expand the current understanding of how anti-CD20 monoclonal antibodiesSearch drug engage with immune cells, potentially influencing their therapeutic efficacy across various clinical settings.

Industry Impact and Future Implications

"This collaborative study together with SeromYx represents a significant step in exploring the expansive applications of our human CD20Search term full-length VLP. We are excited to see how our full-length transmembrane proteins contribute to a greater understanding of antibody drug efficacy, driving forward innovations in the field of immunology and more," said John Miao, Senior VP at ACROBiosystemsSearch company.

Lenny Moise, VP of Research at SeromYx, emphasized the broader implications of the research: "This study not only reinforces the importance of comprehensive Fc effector profiling as a critical tool for all mAbs in development, ensuring a deeper understanding of safety and efficacy mechanisms, but also has implications for the development of new anti-CD20Search term mAbs."

The collaboration's findings may inform the development of next-generation anti-CD20Search term therapeutics and provide a framework for comprehensive antibody characterization in drug development programs. The research demonstrates the value of combining advanced platform technologies to unlock new understanding of established therapeutic mechanisms.